Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Takeshi Kawakami

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T. Kawakami1, K. Yamazaki1, E. Oki2, M. Shimokawa3, N. Takahashi4, M. Yokota5, S. Tokunaga6, T. Esaki7, M. Gamoh8, A. Maeda9, Y. Tsuji10, A. Sakai11, K. Hatanaka12, Y. Shimada13, M. Shiozawa14, Y. Komatsu15, H. Okuda16, M. Ohue17, Y. Maehara18

Author affiliations

  • 1 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Department Of Surgery And Science, Graduate School of Medical Sciences Kyushu University, 812-8582 - Fukuoka/JP
  • 3 Clinical research Institute, National Kyushu Cancer Center, 811-1395 - FUKUOKA/JP
  • 4 Department Of Gastroenterology, Saitama Cancer Centr, 362-0806 - Saitama/JP
  • 5 General Surgery, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP
  • 6 Medical Oncology, Osaka City General Hospital, Osaka/JP
  • 7 Gastrointestinal And Medical Oncology, National Kyushu Cancer Center, Fukuoka/JP
  • 8 Department Of Medical Oncology, Osaki Citizen Hospital, 989-6183 - Osaki/JP
  • 9 Surgery, Ogaki Municipal Hospital, Ogaki/JP
  • 10 Medical Oncology, Tonan Hospital, 060-0001 - Sapporo/JP
  • 11 Gastroenterology, Hyogo Cancer Center, Akashi/JP
  • 12 Gastroenterology, Hakodate Municipal Hospital, Hakodate/JP
  • 13 Clinical Oncology, Kochi Health Sciences Center, Kochi/JP
  • 14 Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama/JP
  • 15 Cancer Chemotherapy, Hokakido University Cancer Center, Sapporo/JP
  • 16 Medical Oncology, Keiyukai Sapporo Hospital, Sapporo/JP
  • 17 Department Of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka/JP
  • 18 -, Kyushu Central Hospital of the Mutural Aid Association of Public School Teachers, Fukuoka/JP
More

Resources

Abstract 1670

Background

Randomized phase 3 trials, RECOURSE and TERRA, established trifluridine/tipiracil (FTD/TPI) as a salvage-line therapy for patients with metastatic colorectal cancer (mCRC). This retrospective, large cohort study, JFMC50, aims to assess the treatment pattern and outcomes of FTD/TPI for mCRC in routine clinical practice.

Methods

We collected data of patients with mCRC who received FTD/TPI during July 2014-September 2016 in Japanese institutions. However, we examined patients who fulfilled the eligibility criteria, through their backgrounds, treatment course, clinical outcomes, including the OS, time to treatment failure (TTF), disease control rate (DCR), and safety. The main eligibility criteria were the ECOG performance status (PS) 0-2 and the starting dose of FTD/TPI close to the standard dose.

Results

From 127 Japanese institutions, we collected data of 2030 patients and assessed 1770 patients. Patients’ backgrounds were the median age [67 (23-92) years], males (60.1%), ECOG PS 0/1/2 (33.7%/56.7%/9.5%), right-sided tumor (25.4%), and prior regorafenib treatment (23.3%). The median OS and TTF were 8.1 and 2.7 months, respectively; the DCR was 21.0%. Major grade 3 or 4 adverse events were leukopenia, neutropenia, and anemia (25.9%, 39.3%, and 17.7%, respectively). At the data cutoff date, 1756 patients discontinued FTD/TPI therapy. The median OS because of treatment termination due to disease progression was 11.6 months in the progression after progressive disease (PD) by RECIST (n = 122), 9.2 months in PD by RECIST (n = 930), 7.8 months in the elevation of tumor marker (n = 109), and 4.9 months in clinical PD (n = 206).

Conclusions

Both efficacy and safety of FTD/TPI in the clinical practice were compatible with clinical trials. The continuous use of FTD/TPI after PD by RECIST could contribute to longer survival; however, further investigation is warranted.

Clinical trial identification

UMIN000027585.

Legal entity responsible for the study

Japanese Foundation for Multidisciplinary Treatment of Cancer.

Funding

Taiho Pharmaceutical Co., Ltd.

Editorial Acknowledgement

The authors would like to thank Enago for the English language review.

Disclosure

T. Kawakami: Honoraria: Takeda, Chugai Pharma, Merck Serono, Lilly Japan, Taiho Pharmaceutical. K. Yamazaki: Speaker's bureau: Chugai, Takeda, Taiho, Yakult, Merck Serono, Lili, Sanofi, Bayer. E. Oki: Speakers' bureau: Taiho Pharmaceutical, Chugai. M. Shimokawa: Statistical consulting fee: Sysmex. T. Esaki: Speakers' bureau from Taiho, Bristol, Eli Lilly, Eisai, Daiichi-Sankyo, Merck Serono, Chugai, Ono, Takeda; Research funding: Daiichi-Sankyo, Merck Serono, Taiho, MSD, Novartis, Dainippon Sumitomo, Ono; Honoraria: Eli Lilly, Kyowa Kirin. Y. Tsuji: Honoraria: Merck Serono, Eli Lilly Japan, Chugai, Taiho, Ono, Daiichi Sankyo, Yakult Honsha, Eisai and Medicon outside the submitted work. Y. Shimada, Y. Komatsu: Research funding, Honoraria: Taiho Pharmaceutical. M. Ohue: Speakers' bureau: Taiho Pharmaceutical; Research funding: Taiho Pharmaceutical, Chugai. Y. Maehara: Speakers' bureau, Research funding: Taiho Pharmaceutical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings